Tonix Pharmaceuticals Holding Corp. (TNXP)
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $13.1M
- Net income
- -$124.0M
- Total assets
- $277.2M
- Market cap
- $176.5M
- Gross margin
- 49.3%
- Operating margin
- -959.1%
- Net margin
- -946.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $13.1M
- Cost of revenue
- $6.6M
- Gross profit
- $6.5M
- Operating expenses
- $132.2M
- Operating income
- -$125.7M
- Net income
- -$124.0M
- EPS (basic)
- $-14.57
- EPS (diluted)
- $-14.57
Balance sheet
- Total assets
- $277.2M
- Current assets
- $228.9M
- Total liabilities
- $32.0M
- Current liabilities
- $30.8M
- Shareholders’ equity
- $245.2M
Cash flow
- Operating cash flow
- -$99.8M
- Investing cash flow
- -$4.5M
- Financing cash flow
- $214.5M
- Net cash flow
- $110.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $176.5M
- EPS (diluted)
- $-14.57
- Shares outstanding
- 17.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 13, 2009
Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price
- Reported a net loss of $124.0M in FY2025.
- Gross margin of 49.3%, net margin -946.2%.
- Trading 84% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tonix Pharmaceuticals Holding Corp..
Write a review
News about Tonix Pharmaceuticals Holding Corp.
News & sentiment via Polygon.io
Tonix Pharmaceuticals Holding Corp.: frequently asked questions
Is Tonix Pharmaceuticals Holding Corp. an American company?
Tonix Pharmaceuticals Holding Corp. is a US-based company headquartered in Berkeley Heights, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Tonix Pharmaceuticals Holding Corp. headquartered?
Tonix Pharmaceuticals Holding Corp. is headquartered in Berkeley Heights, New Jersey, United States.
Is Tonix Pharmaceuticals Holding Corp. publicly traded?
Yes — Tonix Pharmaceuticals Holding Corp. is a publicly traded company. Its stock trades under the ticker symbol TNXP on the NASDAQ.
What does Tonix Pharmaceuticals Holding Corp. do?
Tonix Pharmaceuticals Holding Corp. is an American Pharmaceuticals company in the Health & Beauty sector.
